Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Rat, Hamster, Rabbit, Xenopus (at least 90% immunogen sequence identity)
Protein G purified
Western blot (2 - 5 µg/ml)
AML1 / RUNX1 antibody was raised against a peptide corresponding to a sequence that is homologous in AML-1 and AML-1/ETO [amino acids 231 to 245 (AFNPQPQSQMQDTRQ) of human origin]. Percent identity by BLAST analysis: Human, Chimpanzee, Gorilla, Gibbon, Monkey, Marmoset, Bovine, Dog, Panda, Horse, Pig (100%); Mouse, Rat, Hamster, Rabbit, Xenopus (93%); Elephant, Opossum (87%).
A peptide corresponding to a sequence that is homologous in AML-1 and AML-1/ETO (amino acids 231 to 245 of human origin).
CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter.